BRIEF-Astrazeneca Says Tremelimumab Accepted Under Priority Review In U.S.

Reuters | Updated: 25-04-2022 12:17 IST | Created: 25-04-2022 12:15 IST

AstraZeneca PLC:

* ASTRAZENECA PLC - TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO

* ASTRAZENECA - TREMELIMUMAB ACCEPTED UNDER PRIORITY REVIEW IN US FOR PATIENTS WITH UNRESECTABLE LIVER CANCER IN COMBINATION WITH IMFINZI Source text for Eikon: Further company coverage:

OPINION / BLOG / INTERVIEW

Few-shot AI approach helps decode vaccine hesitancy narratives on social media

Public health AI needs clear rules on data, equity and accountability

Cost, trust and data fears slow AI adoption on Midwest farms

ChatGPT-style AI models struggle to separate stereotypes from social facts

DevShots

Latest News

Connect us on

Facebook Twitter LinkedIn Quora Youtube

Google News RSS

Give Feedback

Name

Message

BRIEF-Astrazeneca Says Tremelimumab Accepted Under Priority Review In U.S.

TRENDING

Delhi High Court to Rehear CBI's Plea Against Kejriwal's Discharge in Excise...

Global Business Strains Under U.S.-Iran Conflict

From ₹50,000 to a Billion Dollar Dream: The Organic Rise of Team Computers

NSE Launches Live Trading in Electronic Gold Receipts, Transforming Gold Mar...

OPINION / BLOG / INTERVIEW

Few-shot AI approach helps decode vaccine hesitancy narratives on social media

Public health AI needs clear rules on data, equity and accountability

Cost, trust and data fears slow AI adoption on Midwest farms

ChatGPT-style AI models struggle to separate stereotypes from social facts

DevShots

Latest News

G7 Sanctions: A Call to Action

Keir Starmer Faces Leadership Challenge Amid Labour Party Turmoil

Bootstrapped Success: Team Computers' Unique Journey in Enterprise IT

Delhi High Court to Rehear CBI's Plea Against Kejriwal's Discharge in Excise Policy Case

Global Business Strains Under U.S.-Iran Conflict

Connect us on

SECTORS

EDITIONS

OTHER LINKS

OTHER PRODUCTS

CONNECT